Lack of efficacy of neoadjuvant chemotherapy in adult patients with maxillo-facial high-grade osteosarcomas: A French experience in two reference centers.

Fiche publication

Date publication

août 2019

Journal

Oral oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MALOUF Gabriel

Tous les auteurs :
Bouaoud J, Beinse G, Epaillard N, Amor-Sehlil M, Bidault F, Brocheriou I, Hervé G, Spano JP, Janot F, Boudou-Rouquette P, Benassarou M, Schouman T, Goudot P, Malouf G, Goldwasser F, Bertolus C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31345398

Résumé

Neoadjuvant chemotherapy (neo-CT) for osteosarcomas is the standard of care. Management of maxillo-facial osteosarcomas (MFOS) is challenging. In this rare disease, we collected a large cohort of patients with the aim to report the histological and radiological local response rates to neo-CT.